COVIRNA - A pronostic test for COVID-19 patients

The COVIRNA project, led by the Luxembourg Institute of Health (LIH), is  one of the 23 research projects awarded within the framework of the Horizon 2020 call for Expression of Interest  “Innovative and rapid health-related approaches to respond to COVID-19 and to deliver quick results for society for a higher level of preparedness of health systems”.

Objectives and methodology

The COVIRNA project aims to generate a diagnostic test based on cardiovascular RNA biomarkers highly predictive of the clinical outcomes of COVID-19 patients and to enable its rapid market uptake with the aim to improve individualised surveillance, care and follow-up of these patients in the context of the current pandemic.

At the technological and research levels:

• To build a biobank of 2,000 blood samples from existing cohorts of COVID-19 patients throughout Europe to perform a retrospective multicentre international study;

• To achieve biomarker qualification and select a subset of highly specific lncRNAs predictive of COVID-19 clinical outcome using bioinformatics, artificial intelligence (AI) and biostatistics;

• To build a disease evolution prediction model based on selected lncRNAs and clinical data;

• To design a reliable, cost-efficient and easy to use in vitro diagnostic (IVD) test to predict COVID-19 clinical outcomes.

At the socio-economic and regulatory levels:

• To achieve CE marking of the innovative COVIRNA prognostic solution;

• To establish a strategic science-policy-business-society consultation to optimize the design of the diagnosis solution complying with end-users’ needs, cost-efficiency analysis requirements, current EU regulation and highest quality standards to enable and accelerate their uptake into clinical practice;

• To raise stakeholders’ awareness of advantages brought by the newly designed diagnostic solution as a valuable decision-support tool for healthcare professionals to deliver the best health outcome for the most vulnerable COVID-19 patients, through a tailored dissemination programme;

• Engage communities of stakeholders in sharing practical knowledge on the use of the novel medical technology.

 

EU Consortium

The project aims to improve the cooperation between European research institutions and boasts a complementary consortium of 15 partners including:

• LIH
• Firalis SA
• University of Luxembourg
• Imperial college of science and technology medicine
• Universiteit Maastricht
• European Health Management Association
• Heinrich-Heine-Universitaet Duesseldorf
• The University of Edinburgh
• Internacionalni Univerzitet U Sarajevu
• Policlinico San Donato SPA
• Pharmahungary 2000 Kiserletes Es Klinikai Kutata Sfejlesztesi Korlatoltfelelossefu Tarsasag
• Universitaet Leipzig
• Jožef Stefan Institute
• Fundacio Privada Institut de Recerca de l`Hospital de la Santa Creu i Sant Pau
• Universidade de Coimbra

The COVIRNA project aims to generate a diagnostic test based on cardiovascular RNA biomarkers highly predictive of the clinical outcomes of COVID-19 patients and to enable its rapid market uptake with the aim to improve individualised surveillance, care and follow-up of these patients in the context of the current pandemic.

Financial support

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.

For more info

• Yvan Devaux, PhD - CVRU Group Leader